Symposia

Arranged in conjunction with key healthcare professionals in the immunotherapy field.

Our symposia are designed to help keep healthcare professionals informed about the latest advancements in ECP. If you missed our symposia in 2025, take a look at the recordings on-demand below.

Upcoming Symposia
Past Symposia

Nov 20, 2026

Symposium at Educational Course on Infections and Complications After Stem Cell Transplantation and CAR T cell Therapy: The use of ECP in modern cGvHD management

Madrid, Spain

Oct 15, 2026

Journées de la Pitié Clinical Symposium: Save the Date

Paris, France

Oct 8, 2026

EORTC 2026 Clinical Symposium: ECP in CTCL Management: Learning from Real-World Experience in Clinical Practice

Berlin, Germany

Oct 1, 2026

COSTEM 2026: Meet The Expert Session

Berlin, Germany

Oct 1, 2026

Symposium at Scientific Meeting of the Slovenian Association of Transfusion Medicine: The role of extracorporeal photopheresis in heart and lung transplantation: From treatment to prevention

Ljubljana, Slovenia

Sep 29, 2026

UKPS 2026 Therakos sponsored session: How does ECP for GvHD sit in 2026?

London, UK

Filter by:

Sep 28, 2026

SITO 2026 Clinical Symposium: Immunomodulation after Transplantation: The role of ECP

Bari, Italy

Sep 24, 2026

DGTI 2026 Clinical Symposium: The high-risk patient: Preparation, treatment and management

Stuttgart, Germany

Sep 11, 2026

Symposium at EBMT 11th Int. Transplant and Cellular Therapy Course: Advancing immunomodulation in GvHD special populations

Barcelona, Spain

Sep 11, 2026

ADO 2026 Clinical Symposium: CTCL in 2026 therapeutic advances and the proposed mechanism of action of ECP

Leipzig, Germany

Sep 10, 2026

17th Int. Congress on Lung Transplantation Clinical Symposium: Shaping the future of lung transplant care: The emerging role of ECP

Paris, France

Mar 22, 2026

EBMT 2026 Clinical Symposium: Understanding the unmet clinical need in GvHD management

Madrid, Spain

View Symposium

Oct 17, 2025

Symposium at EBMT NAP: Advantages of ECP based combinations for the treatment of GvHD

Birmingham, UK

Oct 16, 2025

EORTC 2025 Clinical Symposium: Advancing knowledge on ECP in CTCL

Athens, Greece

Oct 2, 2025

EBMT 2025 TCWP Clinical Symposium: ECP and Ruxolitinib combination in severe steroid—refractory acute GvHD

Dubrovnik, Croatia

Sep 25, 2025

COSTEM 2025: Meet The Expert Session

Berlin, Germany

Sep 18, 2025

DGTI 2025 Clinical Symposium: A focus on the possible MOA: ECP in multiple indications. This event is in German

Mannheim, Germany

Sep 12, 2025

ADO 2025 Clinical Symposium: Extracorporeal photopheresis current status. This event is in German

Essen, Germany

Sep 5, 2025

EBMT 10th International Transplant and Cellular Therapy Course Clinical Symposium: Uncovering emerging evidence to treat GvHD with ECP - Mastering the art of GvHD therapy

University of Barcelona – Faculty of Medicine, Spain

Mar 30, 2025

EBMT 2025 Nurse Symposium: Delivering Therakos ECP: Best Practice in 2025

Florence, Italy

View Symposium

Mar 30, 2025

EBMT 2025 Clinical Symposium: Therakos ECP: A Backbone for GvHD Therapy

Florence, Italy

View Symposium

EBMT 2024 Highlight Report

DISCOVER MORE

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

Indications

The THERAKOS™ CELLEX™ Photopheresis System is indicated for patients older than 18 years of age for the administration of photopheresis in the following:

Cutaneous T Cell Lymphoma (CTCL)
Solid Organ Transplant Rejection (SOT) (heart, lung)

The THERAKOS™ CELLEX™ Photopheresis System is indicated in patients older than 3 years of age for the management of:

Acute and Chronic Graft versus Host Disease (aGvHD, cGvHD)

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients possessing a specific history of a light sensitive disease
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³
Patients who have coagulation disorders or who have previously had a splenectomy

Warnings and Precautions

THERAKOS^TMPhotopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Consult the 8-methoxypsoralen (Methoxsalen (20 micrograms / mL)) professional leaflet or the oral 8-methoxypsoralen formulation package insert before prescribing or dispensing any medication.

Warnings and Precautions

Patients exhibiting multiple basal cell carcinomas or having a history of basal cell carcinoma should be diligently observed and treated.
Methoxsalen may cause fetal harm when given to a pregnant woman. Women undergoing photopheresis should be advised to avoid becoming pregnant.
Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

Symposia

Arranged in conjunction with key healthcare professionals in the immunotherapy field.

Symposium at Educational Course on Infections and Complications After Stem Cell Transplantation and CAR T cell Therapy: The use of ECP in modern cGvHD management

Journées de la Pitié Clinical Symposium: Save the Date

EORTC 2026 Clinical Symposium: ECP in CTCL Management: Learning from Real-World Experience in Clinical Practice

COSTEM 2026: Meet The Expert Session

Symposium at Scientific Meeting of the Slovenian Association of Transfusion Medicine: The role of extracorporeal photopheresis in heart and lung transplantation: From treatment to prevention

UKPS 2026 Therakos sponsored session: How does ECP for GvHD sit in 2026?

SITO 2026 Clinical Symposium: Immunomodulation after Transplantation: The role of ECP

DGTI 2026 Clinical Symposium: The high-risk patient: Preparation, treatment and management

Symposium at EBMT 11th Int. Transplant and Cellular Therapy Course: Advancing immunomodulation in GvHD special populations

ADO 2026 Clinical Symposium: CTCL in 2026 therapeutic advances and the proposed mechanism of action of ECP

17th Int. Congress on Lung Transplantation Clinical Symposium: Shaping the future of lung transplant care: The emerging role of ECP

EBMT 2026 Clinical Symposium: Understanding the unmet clinical need in GvHD management

Symposium at EBMT NAP: Advantages of ECP based combinations for the treatment of GvHD

EORTC 2025 Clinical Symposium: Advancing knowledge on ECP in CTCL

EBMT 2025 TCWP Clinical Symposium: ECP and Ruxolitinib combination in severe steroid—refractory acute GvHD

COSTEM 2025: Meet The Expert Session

DGTI 2025 Clinical Symposium: A focus on the possible MOA: ECP in multiple indications. This event is in German

ADO 2025 Clinical Symposium: Extracorporeal photopheresis current status. This event is in German

EBMT 10th International Transplant and Cellular Therapy Course Clinical Symposium: Uncovering emerging evidence to treat GvHD with ECP - Mastering the art of GvHD therapy

EBMT 2025 Nurse Symposium: Delivering Therakos ECP: Best Practice in 2025

EBMT 2025 Clinical Symposium: Therakos ECP: A Backbone for GvHD Therapy

EBMT 2024 Highlight Report

Discover more

Courses

Webinars

Speaker Meetings

Ask the Expert

Welcome to the Home of ECP

Thank you for visiting therakos.eu.

You are leaving the therakos.eu website.

Welcome to the Therakos Institute

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOSTM PHOTOPHERESIS

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS